Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer types

[1]  P. Tamayo,et al.  APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy , 2018, Oncoimmunology.

[2]  J. Long,et al.  A Comprehensive cis-eQTL Analysis Revealed Target Genes in Breast Cancer Susceptibility Loci Identified in Genome-wide Association Studies. , 2018, American journal of human genetics.

[3]  M. Jia,et al.  APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer , 2018, Oncogene.

[4]  Peter Kraft,et al.  Use of deep whole-genome sequencing data to identify structure risk variants in breast cancer susceptibility genes , 2018, Human molecular genetics.

[5]  P. Lønning,et al.  APOBEC3A/B deletion polymorphism and cancer risk , 2017, Carcinogenesis.

[6]  Gary D Bader,et al.  Association analysis identifies 65 new breast cancer risk loci , 2017, Nature.

[7]  S. Loi,et al.  Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer , 2017, Nature Communications.

[8]  David M. Woods,et al.  Predictors of responses to immune checkpoint blockade in advanced melanoma , 2017, Nature Communications.

[9]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[10]  A. Jakubowska,et al.  The 30 kb deletion in the APOBEC3 cluster decreases APOBEC3A and APOBEC3B expression and creates a transcriptionally active hybrid gene but does not associate with breast cancer in the European population , 2017, Oncotarget.

[11]  E. Jaffee,et al.  Targeting neoantigens to augment antitumour immunity , 2017, Nature Reviews Cancer.

[12]  I. Tsigelny,et al.  High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations , 2017, Oncoimmunology.

[13]  Pornpimol Charoentong,et al.  Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade , 2016, bioRxiv.

[14]  E. Birney,et al.  Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration , 2016, Nature Communications.

[15]  M. Carpenter,et al.  The DNA cytosine deaminase APOBEC3H haplotype I likely contributes to breast and lung cancer mutagenesis , 2016, Nature Communications.

[16]  Bin Zhu,et al.  Edinburgh Research Explorer Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors , 2022 .

[17]  Qin He,et al.  APOBEC3 deletion increases the risk of breast cancer: a meta-analysis , 2016, Oncotarget.

[18]  Zlatko Trajanoski,et al.  Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade , 2016, bioRxiv.

[19]  S. Teo,et al.  Germline APOBEC3B deletion is associated with breast cancer risk in an Asian multi-ethnic cohort and with immune cell presentation , 2016, Breast Cancer Research.

[20]  M. Manikandan,et al.  Analysis of APOBEC3A/3B germline deletion polymorphism in breast, cervical and oral cancers from South India and its impact on miRNA regulation , 2016, Tumor Biology.

[21]  M. Stratton,et al.  Mutational signatures associated with tobacco smoking in human cancer , 2016, Science.

[22]  K. Hemminki,et al.  Analysis of functional germline variants in APOBEC3 and driver genes on breast cancer risk in Moroccan study population , 2016, BMC Cancer.

[23]  Asha A. Nair,et al.  Identification of candidate genes for prostate cancer-risk SNPs utilizing a normal prostate tissue eQTL data set , 2015, Nature Communications.

[24]  C. Swanton,et al.  APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity. , 2015, Cancer discovery.

[25]  Bert Vogelstein,et al.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.

[26]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[27]  T. Blankenstein,et al.  Targeting cancer-specific mutations by T cell receptor gene therapy. , 2015, Current opinion in immunology.

[28]  M. Taheri,et al.  APOBEC3 Deletion is Associated with Breast Cancer Risk in a Sample of Southeast Iranian Population , 2015, International journal of molecular and cellular medicine.

[29]  Ash A. Alizadeh,et al.  Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.

[30]  Reuben S Harris,et al.  APOBEC3B: Pathological consequences of an innate immune DNA mutator , 2015, Biomedical journal.

[31]  Benjamin Haibe-Kains,et al.  APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation , 2015, Proceedings of the National Academy of Sciences.

[32]  Simon Wain-Hobson,et al.  A prevalent cancer susceptibility APOBEC3A hybrid allele bearing APOBEC3B 3′UTR enhances chromosomal DNA damage , 2014, Nature Communications.

[33]  Serena Nik-Zainal,et al.  Mechanisms underlying mutational signatures in human cancers , 2014, Nature Reviews Genetics.

[34]  Adam P Butler,et al.  Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer , 2014, Nature Genetics.

[35]  Wei Zheng,et al.  APOBEC3 deletion polymorphism is associated with breast cancer risk among women of European ancestry. , 2013, Carcinogenesis.

[36]  L. Loeb,et al.  APOBEC3B mutagenesis in cancer , 2013, Nature Genetics.

[37]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[38]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[39]  N. A. Temiz,et al.  Evidence for APOBEC3B mutagenesis in multiple human cancers , 2013, Nature Genetics.

[40]  Steven A. Roberts,et al.  An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers , 2013, Nature Genetics.

[41]  Wei Lu,et al.  A common deletion in the APOBEC3 genes and breast cancer risk. , 2013, Journal of the National Cancer Institute.

[42]  M. Stratton,et al.  DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis , 2013, eLife.

[43]  Stefan Michiels,et al.  Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Jason B. Nikas,et al.  APOBEC3B is an enzymatic source of mutation in breast cancer , 2013, Nature.

[45]  I. Willner,et al.  APOBEC3G enhances lymphoma cell radioresistance by promoting cytidine deaminase-dependent DNA repair. , 2012, Blood.

[46]  A. Børresen-Dale,et al.  Mutational Processes Molding the Genomes of 21 Breast Cancers , 2012, Cell.

[47]  Morten Nielsen,et al.  NetMHCcons: a consensus method for the major histocompatibility complex class I predictions , 2011, Immunogenetics.

[48]  K. Hemminki,et al.  Impact of functional germline variants and a deletion polymorphism in APOBEC3A and APOBEC3B on breast cancer risk and survival in a Swedish study population , 2015, Journal of Cancer Research and Clinical Oncology.